Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.90 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203300 | 1.00 | CYP3A4 (0.90) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12098465 | 1.00 | CYP3A4 (0.90) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL14708713 | 1.00 | CYP3A4 (0.90) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL203451 | 0.99 | CYP3A4 (0.91) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL2707660 | 0.99 | CYP3A4 (0.91) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL18020333 | 0.97 | CYP3A4 (0.85) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL205850 | 0.95 | CYP3A4 (0.98) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL17066717 | 0.95 | CYP3A4 (0.98) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL2756813 | 0.95 | CYP3A4 (0.98) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL2708683 | 0.95 | CYP3A4 (0.98) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154871-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011028596-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885KCNH2 4228/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | CYP3A4 177/4885CYP2C9 519/4885KCNH2 4324/4885 |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | CYP3A4 237/4885CYP2C9 322/4885KCNH2 4035/4885 |
| US-20110152237-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | CYP3A4 52/4885CYP2C9 40/4885KCNH2 2695/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885KCNH2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.